Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-ibritumomab Tiuxetan Consolidation in Bulky DLBCL
NCT01157988Phase 2Completed
- Sponsor
- Chonnam National University Hospital
- Start
- Jan 2007
- Primary completion
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by Chonnam National University Hospital. Primary endpoints: Objective Response at 24 weeks and Safety and Toxicity at 3 years. Started Jan 2007; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01157988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01157988.